Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Income from Continuing Operations (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Income from Continuing Operations data on record, last reported at 9753000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 3.51% year-over-year to 9753000.0; the TTM value through Dec 2025 reached 39227000.0, down 30.62%, while the annual FY2025 figure was 39227000.0, 30.56% down from the prior year.
  • Income from Continuing Operations reached 9753000.0 in Q4 2025 per TLSI's latest filing, up from 10811000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2836725.0 in Q1 2022 and bottomed at 44342166.0 in Q4 2022.
  • Average Income from Continuing Operations over 4 years is 10991495.25, with a median of 9020500.0 recorded in 2025.
  • The widest YoY moves for Income from Continuing Operations: up 82.39% in 2023, down 686.85% in 2023.
  • A 4-year view of Income from Continuing Operations shows it stood at 44342166.0 in 2022, then rose by 19.5% to 35696000.0 in 2023, then surged by 71.68% to 10108000.0 in 2024, then increased by 3.51% to 9753000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 9753000.0 in Q4 2025, 10811000.0 in Q3 2025, and 8288000.0 in Q2 2025.